OIS at AAO 2015

Nov 12, 2015 ‐ Nov 12, 2015

The Ophthalmology Innovation Summit was created to facilitate meaningful interactions and business partnerships between physicians, entrepreneurs, investors, and industry executives who are driving ophthalmic innovation. OIS addresses key issues – both hurdles and opportunities while showcasing the most promising private ophthalmic companies.


Welcome & Chairman's 2015 Year in Review

Nov 12, 2015 8:15am ‐ Nov 12, 2015 8:30am


Drug Delivery Company ShowcaseDrug Delivery Company Showcase

Preview Available

Drug Delivery Company Showcase

Nov 12, 2015 8:30am ‐ Nov 12, 2015 9:10am

This showcase will include speakers from Ocular Therapeutix, ForSight VISION5, Envisia Therapeutics, Mati Therapeutics and GrayBug

Moderator(s): Speaker(s):

ForSight VISION5ForSight VISION5

Preview Available

ForSight VISION5

Nov 12, 2015 8:38am ‐ Nov 12, 2015 8:46am

ForSight VISION5 is focused on developing non-invasive drug delivery products that replace eye drops and provide sustained therapy for major eye diseases. The lead product candidate is the Helios insert, a novel, non-invasive delivery system designed to allow glaucoma and ocular hypertensive patients to receive medication continually.


Envisia TherapeuticsEnvisia Therapeutics

Preview Available

Envisia Therapeutics

Nov 12, 2015 8:46am ‐ Nov 12, 2015 8:54am

Envisia Therapeutics, formed by Liquidia Technologies in 2013, is a privately held biotechnology company focused on the development of novel ocular therapies. Envisia is leveraging the unique and powerful properties of the PRINT® technology to develop therapies for a variety of ocular conditions, beginning with ENV515 for glaucoma.


Mati TherapeuticsMati Therapeutics

Preview Available

Mati Therapeutics

Nov 12, 2015 8:54am ‐ Nov 12, 2015 9:02am

Mati Therapeutics Inc. is developing an enhanced drug delivery platform to administer therapeutics to the eye. Due to Mati’s ability to adjust this platform, this technology can be used to treat a range of ophthalmic conditions with multiple therapies in late stage development.



Preview Available


Nov 12, 2015 9:02am ‐ Nov 12, 2015 9:10am

GrayBug is developing injectable controlled release technologies to reduce the frequency of ocular therapy to a few times per year (2-3 per year). These technologies have solved the problems with tolerability and blockage of vision noted with many injectable sustained release ocular products for wet AMD and glaucoma.


Device & Diagnostics Company Showcase

Nov 12, 2015 9:10am ‐ Nov 12, 2015 10:14am

This showcase will include speakers from Transcend Medical, AcuFocus, ReVision Optics, Avedro, Clarvista Medical, Myriosys Cellular Devices, Powervision, and RPS Diagnostics


Transcend MedicalTranscend Medical

Preview Available

Transcend Medical

Nov 12, 2015 9:10am ‐ Nov 12, 2015 9:18am

Transcend Medical is focused on the development of technologies to transform the treatment of glaucoma, the leading cause of adult irreversible blindness. Our flagship product, the CyPass® Micro-Stent, is a next-generation, minimally invasive device designed to enhance aqueous outflow to the suprachoroidal space, part of the eye’s natural drainage systems.

  • Sean Ianchulev, MD, MPH, CMO & VP, Medical Affairs & Business Development, Transcend Medical


Preview Available


Nov 12, 2015 9:18am ‐ Nov 12, 2015 9:26am

AcuFocus Inc., a privately held ophthalmic medical device company, develops and markets breakthrough technologies for the improvement of near vision. The Company’s proprietary technology platforms, the KAMRA inlay and the IC-8 IOL, both use small aperture optics to allow focused light rays to reach the retina and extend depth-of-focus.

  • Nick Tarantino, OD, Chief Global Clinical Research & Regulatory Affairs Officer, AcuFocus

ReVision OpticsReVision Optics

Preview Available

ReVision Optics

Nov 12, 2015 9:26am ‐ Nov 12, 2015 9:34am

ReVision Optics®, Inc. is developing and commercializing an innovative optical solution to correct presbyopic vision, or the inability of the eye to focus on near objects.